Immunic (NASDAQ:IMUX) announces that its Phase 2 clinical trial, CALVID-1, evaluating IMU-838 in patients with moderate COVID-19 disease will continue unchanged after the independent Data Monitoring Committee completed its preplanned interim safety analysis.
Thus far, 110 subjects have been enrolled and the trial is progressing well. Target enrollment is ~230 participants.
The company says IMU-838 is an orally available, next-generation immune modulator that dampens the immune response by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH) that plays a key role in intracellular metabolism of activated immune cells.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.